Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
Govindarajan
Rangaswamy
R
Adusumilli
Josna
J
Baxter
Donna L
DL
El-Khoueiry
Anthony
A
Harik
Sami I
SI
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D018281:Cholangiocarcinoma / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib; D013577:Syndrome; D048490:raf Kinases / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D001557:Benzenesulfonates; D004791:Enzyme Inhibitors; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D048490:raf Kinases